Cargando…
Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
CRISPR-based technology has become widely used as an antiviral strategy, including as a broad-spectrum human coronavirus (HCoV) therapeutic. In this work, we have designed a CRISPR-CasRx effector system with guide RNAs (gRNAs) that are cross-reactive among several HCoV species. We tested the efficac...
Autores principales: | Mayes, Cathryn M., Santarpia, Joshua L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457650/ https://www.ncbi.nlm.nih.gov/pubmed/36912815 http://dx.doi.org/10.1089/crispr.2022.0095 |
Ejemplares similares
-
Evaluating the Impact of gRNA SNPs in CasRx Activity for Reducing Viral RNA in HCoV-OC43
por: Mayes, Cathryn Michelle, et al.
Publicado: (2022) -
Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021) -
Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007) -
Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023) -
Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)